Detalles de la búsqueda
1.
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Nature
; 609(7926): 369-374, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36045296
2.
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
N Engl J Med
; 390(16): 1467-1480, 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38657244
3.
Reprogramming natural killer cells for cancer therapy.
Mol Ther
; 2024 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38273655
4.
Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
Cancer
; 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578977
5.
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
Blood
; 139(23): 3376-3386, 2022 06 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35338773
6.
Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation.
Eur J Haematol
; 112(1): 94-101, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37477866
7.
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)-T cell therapy in patients with hematological malignancy.
Eur J Haematol
; 112(2): 257-265, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37698159
8.
A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome.
Mol Biol Rep
; 51(1): 561, 2024 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38643442
9.
Survival and late mortality among patients who survived disease-free for 2 years after stem cell transplantation.
Br J Haematol
; 202(3): 608-622, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306071
10.
Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
Br J Haematol
; 202(3): 517-524, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37192741
11.
A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
Cytotherapy
; 25(11): 1167-1175, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37480884
12.
Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.
Cytotherapy
; 25(2): 192-201, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36496302
13.
Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
BMC Cancer
; 23(1): 1055, 2023 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37919691
14.
Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study.
Support Care Cancer
; 30(4): 3321-3327, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34988704
15.
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia.
Mol Ther
; 29(2): 645-657, 2021 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33278564
16.
Progress on CAR-T cell therapy for hematological malignancies.
Zhejiang Da Xue Xue Bao Yi Xue Ban
; 51(2): 192-203, 2022 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36161291
17.
Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Zhejiang Da Xue Xue Bao Yi Xue Ban
; 51(2): 167-174, 2022 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36161292
18.
Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.
Zhejiang Da Xue Xue Bao Yi Xue Ban
; 51(2): 185-191, 2022 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36161298
19.
Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
Zhejiang Da Xue Xue Bao Yi Xue Ban
; 51(2): 144-150, 2022 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36161293
20.
Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Zhejiang Da Xue Xue Bao Yi Xue Ban
; 51(2): 160-166, 2022 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36161295